Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE6D | O43924 | 2/20 | 0.36 |
| ▸ | PDE6A | P16499 | 2/20 | 0.36 |
| ▸ | PDE6G | P18545 | 2/20 | 0.36 |
| ▸ | PDE6B | P35913 | 2/20 | 0.36 |
| ▸ | PDE6C | P51160 | 2/20 | 0.36 |
| ▸ | PDE6H | Q13956 | 2/20 | 0.36 |
| ▸ | RORC | P51449 | 14/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23830354 | 0.89 | SCN9A (0.36) | PDE6DPDE6APDE6GPDE6BPDE6C | |
| SCHEMBL23830367 | 0.88 | PDE6D (0.35) | PDE6DPDE6APDE6GPDE6BPDE6C | |
| SCHEMBL23830336 | 0.86 | RORC (0.35) | RORCP2RX7 | |
| SCHEMBL23830378 | 0.85 | CSF1R (0.41) | PDE6DPDE6APDE6GPDE6BPDE6C | |
| SCHEMBL23830374 | 0.84 | RORC (0.36) | RORCP2RX7 | |
| SCHEMBL23830327 | 0.82 | PDE6D (0.52) | PDE6DPDE6APDE6GPDE6BPDE6C | |
| SCHEMBL23830390 | 0.82 | P2RX7 (0.34) | RORCP2RX7 | |
| SCHEMBL23830274 | 0.81 | P2RX7 (0.38) | RORCP2RX7 | |
| SCHEMBL23830351 | 0.77 | P2RX7 (0.35) | RORCP2RX7 | |
| SCHEMBL23830280 | 0.76 | PDE6D (0.44) | PDE6DPDE6APDE6GPDE6BPDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292333-A1 | CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA | CADILA HEALTHCARE LIMITED (IN) | 2021-09-23 | — | — | US | claimed |
| CN-112543757-A | Condensed azaheteroaryl compounds having antibacterial activity against tubercle bacillus | 卡迪拉保健有限公司 | 2021-03-23 | — | — | CN | claimed |
| US-20210292333-A1 | CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA | CADILA HEALTHCARE LIMITED (IN) | 2021-09-23 | — | — | US | disclosed |
| CN-112543757-A | Condensed azaheteroaryl compounds having antibacterial activity against tubercle bacillus | 卡迪拉保健有限公司 | 2021-03-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292333-A1 | CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA | DPEP1, SAT1, PEPD | PDE6D 3804/4885PDE6A 1704/4885PDE6G 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.